STING1 and non-small cell lung carcinoma: Recent increasing evidence showed that the activation of STING pathway was significantly associated with anti-tumor responses such as non-small cell lung Cancer (NSCLC), small cell lung cancer (SCLC), pancreatic ductal adenocarcinoma (PDACs), and colorectal cancer (CRC) [13, 17–21].